Rende Jonathan
Chief Research & Dev. Officer at CASTLIGHT HEALTH, INC.
- Sold, on record
- $253k
- Dollars the filings state
- Form 4 sales
- 4
- Latest Feb 17, 2017
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- CASTLIGHT HEALTH, INC.Chief Research & Dev. Officer
Sales by reason
0
Routine
0
Plan not stated
0
No plan
0
Unusual
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale CASTLIGHT HEALTH, INC.UnusualMay 16, 2016 2016
Sold 30,771 shares at $3.33 ($102k)
Rende Jonathan, Chief Research & Dev. Officer
Sold 37.9% of holdings ($271k position)50,479 shares leftFirst sale on recordFiling
- 2 Form 4 sale CASTLIGHT HEALTH, INC.Plan not statedAug 16, 2016 +92 days
Sold 8,286 shares at $4.25 ($35k)
Rende Jonathan, Chief Research & Dev. Officer
Sold 11.7% of holdings ($301k position)62,505 shares leftFiling
- 3 Form 4 sale CASTLIGHT HEALTH, INC.Plan not statedNov 16, 2016 +92 days
Sold 7,794 shares at $4.99 ($39k)
Rende Jonathan, Chief Research & Dev. Officer
Sold 9.4% of holdings ($413k position)75,024 shares leftFiling
- 4 Form 4 sale CASTLIGHT HEALTH, INC.Plan not statedFeb 17, 2017 +93 days
Sold 20,916 shares at $3.65 ($76k)
Rende Jonathan, Chief Research & Dev. Officer
Sold 16.5% of holdings ($462k position)105,670 shares left2.5x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (4)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2017 | Feb 17, 2017 | CASTLIGHT HEALTH, INC. | Chief Research & Dev. Officer | Form 4 sale | 20,916 | $76k | 16.5% | Plan not stated | SEC |
| Nov 16, 2016 | Nov 17, 2016 | CASTLIGHT HEALTH, INC. | Chief Research & Dev. Officer | Form 4 sale | 7,794 | $39k | 9.4% | Plan not stated | SEC |
| Aug 16, 2016 | Aug 17, 2016 | CASTLIGHT HEALTH, INC. | Chief Research & Dev. Officer | Form 4 sale | 8,286 | $35k | 11.7% | Plan not stated | SEC |
| May 16, 2016 | May 17, 2016 | CASTLIGHT HEALTH, INC. | Chief Research & Dev. Officer | Form 4 sale | 30,771 | $102k | 37.9% | Unusual | SEC |